For anyone curious if this corporate strategy aligns with other biotech companies and their approach, this is a quick ChatGPT summary of success cases:
I, like many thousands of RAC investors who bought in early 2021, am still carrying a paper loss of more than 35% (though it's been as low as nearly 70% at certain points). This is AFTER averaging down to sub $2.50 and increasing my holding to more than 110000 shares in two accounts. I consider this sustained support for the company and demonstrated belief in the potential for return.
Patience is very difficult, but must be weighed now against this potential. Not all RAC holders are fortunate enough to be free carrying - and in fact, given how illiquid the stock is, most are absolutely demonstrating patience every day.
I do wonder what prompted this post - if there are simply enough shareholders asking the same question "why not just raise and dilute?" Or is the point about "patience" also a timely reminder when there are certain pieces of news many are expecting soon?
